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1  |  INTRODUC TION
Hepatitis B virus (HBV) is a hepatotropic virus responsible for substantial 
morbidity and mortality worldwide. Infection can be acute or chronic, 
with most of the HBV disease burden attributable to chronic disease. 
The World Health Organization (WHO) estimated a chronic HBV (CHB) 
global burden of 257 million CHB-infected individuals for 2015, with 
887,000 HBV-attributable deaths reported in the same year,1 making 
HBV one of the leading causes of morbidity and mortality from viral 
infection, for which the burden has increased in recent decades.2
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Abstract
Hepatocellular carcinoma (HCC) is one of the leading contributors to cancer mortality 
worldwide and is a leading cause of death in individuals with chronic hepatitis B virus 
(HBV) infection. It is uncertain how the presence of other metabolic factors and co-
morbidities influences HCC risk in HBV. Therefore, we performed a systematic litera-
ture review and meta-analysis to seek evidence for significant associations. MEDLINE, 
EMBASE and Web of Science databases were searched from 1 January 2000 to 24 
June 2020 for studies investigating associations of metabolic factors and comorbidi-
ties with HCC risk in individuals with chronic HBV infection, written in English. We 
extracted data for meta-analysis and generated pooled effect estimates from a fixed-
effects model. Pooled estimates from a random-effects model were also generated 
if significant heterogeneity was present. We identified 40 observational studies re-
porting on associations of diabetes mellitus (DM), hypertension, dyslipidaemia and 
obesity with HCC risk. Only DM had a sufficient number of studies for meta-analysis. 
DM was associated with >25% increase in hazards of HCC (fixed-effects hazards ratio 
[HR] 1.26, 95% confidence interval (CI) 1.20–1.32, random-effects HR 1.36, 95% CI 
1.23–1.49). This association was attenuated towards the null in a sensitivity analysis 
restricted to studies adjusted for metformin use. In conclusion, in adults with chronic 
HBV infection, DM is a significant risk factor for HCC, but further investigation of the 
influence of antidiabetic drug use and glycaemic control on this association is needed. 
Enhanced screening of individuals with HBV and diabetes may be warranted.
K E Y W O R D S
comorbidities, diabetes, HCC, Hepatitis B virus, hepatocellular carcinoma
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2020 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.
494  |    CAMPBELL Et AL.
CHB deathsdue to primary liver cancer and cirrhosis account for 
the majority of deaths attributable to viral hepatitis. A Global Burden 
of Disease study on the global hepatocellular carcinoma (HCC) bur-
den reported a 42% increase in incident cases of HCC attributable to 
CHB infection between 1990 and 2015,3 among which CHB infec-
tion was the largest contributor, responsible for more than 30% of 
incident cases in 2015.3
Multiple risk factors for HCC in CHB-infected individuals have 
been established, including sex, age, cirrhosis and co-infection 
with human immunodeficiency virus (HIV) or other hepatitis vi-
ruses (including hepatitis C and D). Previous studies have inves-
tigated associations of comorbidities, such as diabetes mellitus 
(DM)4-7 and hypertension,8,9 with risk of HCC in the general pop-
ulation, and The European Association for the Study of the Liver 
(EASL) recognizes DM as a risk factor for HCC in CHB.10 As the 
global prevalence of comorbidities such as DM,11 renal disease,12 
hypertension13 and coronary heart disease (CHD)14 continues to 
rise, these conditions are increasingly relevant to the development 
of HCC.
Various risk scores have been developed to predict HCC risk: the 
PAGE-B risk score was developed to predict HCC risk in Caucasian pa-
tients on antiviral treatment,15 while the REACH-B,16,17 GAG-HCC18,19 
and CU-HCC18,20-22 risk scores apply to untreated Asian populations. 
Existing risk scores use age, sex and HBV DNA viral load (VL) to pre-
dict risk. CU-HCC and GAG-HCC include parameters for cirrhosis; 
however, no score accounts for comorbidities such as DM or hyper-
tension. It is possible that risk prediction could be improved by incor-
porating these comorbid conditions.
Despite rises in the global prevalence of relevant comorbid-
ities, evidence concerning associations of comorbidities with 
HCC risk in CHB is poor and heterogeneous. Neither EASL, the 
American Association of the Study of Liver Disease (AASLD)23 nor 
the Asian Pacific Association for the Study of the Liver (APASL)24 
guidelines for HBV management include recommendations for en-
hanced screening or DM management in CHB, despite recent clin-
ical interest in the potential utility of metformin in preventing and 
treating various cancers.25,26 Furthermore, there are few studies 
investigating associations of other potentially relevant comorbidi-
ties (such as hypertension, CHD and renal disease) and their met-
abolic risk factors (such as obesity and dyslipidaemia) with HCC 
risk. Therefore, we undertook a systematic review, aiming to sum-
marize and critically appraise studies investigating associations of 
relevant comorbidities and metabolic factors with risk of HCC in 
CHB-infected individuals.
2  |  METHODS
2.1  |  Search strategy and selection criteria
In June 2020, we systematically searched three databases (Web 
of Science, EMBASE and MEDLINE) in accordance with PRISMA 
guidelines27; search terms are listed in Table S1. We searched all 
databases from 1 January 2000 until 24 June 2020, without appli-
cation of any restrictions for study design applied to search terms 
or results, but including only full-text human studies published in 
English.
We combined and deduplicated search results from the three 
databases, prior to screening for eligibility. We excluded articles not 
investigating associations of comorbidities with risk of HCC and/
or not restricted to CHB-infected participants. We also searched 
reference lists of relevant systematic reviews/meta-analyses and 
studies identified for inclusion to identify additional studies for 
inclusion. Search terms were constructed and agreed on by three 
authors (PM, TW and CC) and articles were screened and selected 
by one author (CC).
2.2  |  Data extraction and statistical analysis
One author (CC) extracted the following summary characteristics 
from included studies: country, publication year, study design, fol-
low-up period, comorbidities investigated, number of participants, 
number of HCC cases, sex, age at baseline, risk ratio and covariates 
adjusted for.
We carried out meta-analysis in R (version 3.5.1) using the 
‘meta’ package (version 4.12-0),28 including only hazard ratios (HRs) 
minimally adjusting for age and sex reported in cohort or nested 
case-control studies. We calculated pooled summary effect esti-
mates using the inverse-variance weighting of HRs on the natural 
logarithmic scale, and quantified between-study heterogeneity 
using the I2 statistic; significance of heterogeneity was investi-
gated using Cochran's Q test (p threshold = 0.05). Where I2 was 
>0 and heterogeneity was significant, we present both fixed- and 
random-effects summary estimates. We undertook multiple sen-
sitivity analyses whereby analyses were restricted to studies ad-
justing for various additional confounders and for DM treatment, 
and stratified by DM type, in order to investigate robustness of 
observed associations.
2.3  |  Definitions
For DM, we considered diagnoses of type 1 and type 2 DM, 
as well as unspecified DM, for pooling the effect, followed by 
further stratification by subtypes of diabetes if enough studies 
were eligible. Hypertension (HT) was defined by either a diag-
nosis of HT recorded as part of the medical history or current 
health assessment, or a measurement with mean arterial pres-
sure (MAP) above a specified threshold. Obesity was based on 
BMI values, by referring to the cut-off in the included studies, 
where 25, 27 and 30 kg/m2 were the common threshold values 
used. Cardiovascular disease (CVD) was defined broadly as an 
umbrella term including any of the following disease subtypes: 
    |  495CAMPBELL Et AL.
ischaemic heart disease (IHD)/coronary heart disease (CHD) and 
cerebrovascular disease. Dyslipidaemia was defined according to 
serum lipid concentrations above a certain threshold defined in 
the primary studies (thresholds may vary depending on health-
care setting).
2.4  |  Quality appraisal
We used the Newcastle-Ottawa Scale (NOS) to assess the quality 
of nonrandomized studies, including cohort and case-control stud-
ies,29 judging studies based on points awarded for selection of study 
groups, comparability of groups and exposure/outcome ascertain-
ment. Studies with scores of <5, 5–7 and >7 points were considered 
to be of low, sufficient and high quality, respectively.
3  |  RESULTS
3.1  |  Study characteristics
In total, our search identified 1,814 articles (899 from MEDLINE, 407 
from EMBASE and 508 from Web of Science) (Figure 1). After dedu-
plication, 1136 individual articles were screened by title/abstract, 
from which 140 full texts were identified for full-text assessment. 
After exclusion of ineligible articles and reference list searching of 
relevant articles, 40 articles were identified for inclusion in this re-
view. Summary characteristics of included studies are reported in 
Table S2.
All studies were observational in design, with 33 cohort and 
seven case-control studies included (Table S2). Thirty-two studies 
were conducted in Asian countries. Four studies were restricted 
to male cohorts, and 36 were undertaken in mixed-sex cohorts. All 
studies recruited participants from health centres, health care or 
prescription databases, or pre-existing cohorts or cancer screening 
programmes. All studies were undertaken in adults, with mean/me-
dian ages of cohorts ranging between 40 and 65 years in 33 stud-
ies. Thirty-three studies investigated DM/insulin resistance/fasting 
serum glucose, 11 investigated blood hypertension/blood pressure, 
seven investigated dyslipidaemia, five investigated obesity and car-
diovascular disease. Fewer than five studies investigated other fac-
tors including renal disease, statin use and use of antidiabetic drugs.
In the 40 studies including 536,456 adults, >30,500 HCC events 
occurred (we are unable to report an exact number, because one 
study did not report a precise number of HCC cases30). Sample sizes 
of cohort studies varied widely, ranging from 102 to 214,167 (me-
dian 3090), with corresponding numbers of HCC cases ranging from 
seven (arising among 102 participants) to 11,241 (arising among 
214,167 participants). Case-control sample sizes ranged from 182 
to 6275 (median 1122) with corresponding numbers of HCC cases 
ranging from 73 (out of 182 participants) and 1105 (out of 6275 
participants).
3.2  |  Quality assessment
Among 40 studies, 39 had quality scores ≥5 (Tables S3 and S4). All 
33 cohort studies were of sufficient quality with 13 of these being 
scored as high quality. Six out of seven case-control studies were 
of sufficient quality and one of poor quality. Inclusion criteria var-
ied widely, and therefore, study populations were heterogeneous. 
In most studies, exposures and outcomes were ascertained using 
health assessment, imaging or record linkage. Twenty-three cohort 
studies and seven case-control studies accounted for age and sex. 
HCC typically arises after long durations of infection, and therefore, 
prolonged follow-ups enable the detection of more HCC events; 
among 23 cohort studies identified, only five cohort studies had 
lengths of follow-up ≥10 years.
3.3  |  Association of diabetes mellitus with HCC risk
Thirty-six studies investigated the association of DM with risk of CHB 
progression to HCC, comprising seven case-control studies (Table 1a) 
and 29 cohort studies (Table 1b). Four studies were restricted to males 
and the others included both sexes (Table S2). Mean ages at baseline in 
all studies were ≥40 years, respectively. Study populations were heter-
ogeneous with variable inclusion criteria, and definitions of DM were 
not consistent between studies. Four case-control and four cohort 
studies investigated type 2 DM/insulin resistance, three case-control 
and seven cohort studies investigated unspecified DM, and one case-
control and three cohort studies investigated both type 1 and 2 DM as 
a composite potential risk factor.
Among the seven case-control studies that reported effect es-
timates there was directional inconsistency between effect esti-
mates, with four studies reporting an increased risk of HCC in those 
with DM as compared to those without, three studies reporting a 
decreased risk of HCC in those with DM, and one study failing to 
provide an effect estimate. Odds ratios (ORs) and HRs >1 ranged 
from 1.35 to 2.04 and all were statistically significant. RRs <1 ranged 
from 0.19 to 0.80, of which two were statistically significant. Among 
28 cohort studies providing effect estimates (27 HRs and 1 OR), 
there was directional consistency with 27 of the reported RRs >1. 
Effect sizes >1 ranged from 1.05 to 6.80, with 15 RRs being statisti-
cally significant. The single RR that was <1 was nonsignificant.
Minimal adjustment for confounders differed between case-con-
trol and cohort studies. Most case-control studies adjusted for age, 
sex, HCV coinfection, HIV coinfection and cirrhosis. Twenty cohort 
studies minimally adjusted for age and sex. Of these, 15 adjusted for 
HCV coinfection, 13 for cirrhosis, 12 for antiviral treatment, 10 for 
HIV coinfection, 9 for alcohol consumption, seven each for HBV viral 
DNA load and cigarette smoking and 6 for other liver disease (includ-
ing alcoholic liver disease). Eight studies excluded participants who 
developed HCC within the first 3 to 12 months of follow-up in their 
main analyses. One study did so in a sensitivity analysis and found 
this did not modify associations observed.
496  |    CAMPBELL Et AL.
3.4  |  Meta-analysis of cohort studies
DM was associated with increased hazards of progression to HCC by meta-
analysis restricted to HRs minimally adjusted for age and sex (Figure 2). 
As there was significant heterogeneity (I2 = 52%, p < 0.01), results from 
both fixed- and random-effects analyses are presented. In random-effects 
analysis, the hazards of HCC were 36% higher (summary HR 1.36; 95% CI 
1.23–1.49) in those with DM as compared to those without DM.
F I G U R E  1  Flow chart of study selection. MEDLINE, EMBASE and Web of Science databases were systematically searched using relevant 
terms to identify relevant human studies published in English from 1 January 2000 to 24 June 2020
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3.5  |  Subgroup and sensitivity analyses
We performed sensitivity analyses in order to investigate the ro-
bustness of pooled estimates to additional adjustment for HCV or 
HIV coinfection, cirrhosis and DM treatment. After restricting meta-
analysis to 16 studies adjusting for HCV coinfection in addition 
to age and sex (Figure S1), pooled HRs did not change materially. 
Considering eight studies adjusting for HIV and antiviral treatment 
(Figure S2), pooled HR from the fixed-effects analysis was attenu-
ated towards the null but remained significant. To investigate the 
robustness of the association of DM with HCC to adjustment for 
cirrhosis, a potential mediator, we restricted meta-analysis to studies 
adjusting for cirrhosis (Figure S3). This did not change pooled HRs 
materially.
To investigate heterogeneity between type 2 DM and unspec-
ified DM, sensitivity analysis was performed whereby studies 
were stratified by DM type. Among studies investigating type 2 
DM, heterogeneity was 33% (p = 0.18) (Figure S4). However, this 
HR did not differ substantially to that observed in the primary 
meta-analysis.
The association of DM with increased HCC risk was attenuated 
towards the null in studies that adjusted for metformin use, with risk 
TA B L E  1 A  Effect estimates for case-control studies investigating the association of diabetes mellitus with hepatocellular carcinoma risk 







Age at baseline, 
years Sex (% male) Source of controls
Relative risk 
measurea 




5932 731 40–90 (range) 56.7 Same insurance 
database as 
cases
aHR 1.35 (1.16 to 1.57)
US, Kennedy 
(2018)33
1101 278 64 78 Same clinical data 
repository as 
cases
aOR 0.60 (0.40 to 0.90)
China, Li 
(2018)71









Hospital controls aOR 2.04 (1.15 to 5.02)
China, Han 
(2017)72
182 73 56.18 (mean) 79.1 Hospital controls N/A N/A
China, Gao 
(2013)32
370 122 54.7 (mean) 86.9 Hospital controls aORb  0.38 (0.18 to 0.81) 
(compensated 
cirrhosis)











Hospital controls aOR 0.80 (0.60 to 1.10)
Taiwan, Chao 
(2011)34










insulin (μU/ml) X 
fasting glucose 
(mmol/l)/22.5)
index scores of <0.46, 
0.78–1.22 and >1.22 
had HRs of 1.48 (0.90 
to 2.44), 0.92 (0.54 to 
1.55) and 1.96 (1.23 
to 3.10) as compared 
to those with a 
HOMA-IR index of 
0.46–0.77
Abbreviations: aHR, adjusted Hazards Ratio; aOR, adjusted Odds Ratio; N/A, not available.
aAdjusted risk ratios are minimally adjusted for age and sex. 
bAdjusted for age but not sex. 
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of HCC 16% higher in DM participants as compared to non-DM (ran-
dom-effects HR 1.16, 95% CI 1.04–1.29) in analysis restricted to studies 
adjusting for metformin use (Figure S5). After restricting to studies ad-
justing to DM treatment, pooled HRs remained statistically significant.
3.6  |  Association of hypertension with 
hepatocellular carcinoma risk
Eleven studies investigated the association of HT with risk of CHB 
progression to HCC, one case-control study and 10 cohort studies 
(Table 2). All studies were mixed-sex samples in which mean/median 
age at baseline was ≥40 years (Table S2). Definitions of HT were het-
erogeneous; most studies ascertained hypertension via record link-
age, but others used health assessment or interview. Few studies 
defined clinical thresholds for hypertension classification. ‘Higher’ 
MAP was the primary exposure of interest in the case-control study, 
for which a threshold was not defined.
Among 10 studies reporting hazards of HCC associated with HT, 
only four HRs were minimally adjusted for age and sex. Out of three 
studies which reported significantly increased hazards of HCC as-
sociated with HT, two reported unadjusted HRs and one reported a 
HR adjusted for age and not sex. Another five studies reported an 
effect in the same direction, but effect sizes were not statistically 
significant. Adjusted HRs >1 ranged from 1.19 to 1.70 and <1 from 
0.04 to 0.96. Adjustment for confounders was poor, with only four 
HRs minimally adjusted for age and sex.
3.7  |  Associations of other comorbidities with 
hepatocellular carcinoma risk
Seven studies investigated the association of dyslipidaemia with 
HCC risk in CHB patients (Table 3). All studies reported reduced 
risks of HCC in participants with dyslipidaemia as compared to those 
without; however, only one HR was statistically significant. Clinical 
definitions of dyslipidaemia were often not reported, and only four 
studies minimally adjusted for age and sex. Six studies investigated 
the association of obesity with HCC risk. Clinical definitions of obe-
sity varied greatly, and out of four studies reporting increased risks 
of HCC with obesity, only one HR was statistically significant.
Three studies investigated the association of statin use with HCC 
risk in CHB. All studies reported HRs <1, and two of these HRs were 
statistically significant. HRs reported in five studies for HCC risk asso-
ciated with CVD varied, likely due to the variable definitions of CVD 
used across studies. Associations for other variables, including respi-
ratory disease and renal disease, were reported by ≤2 studies each.
4  |  DISCUSSION
Our meta-analysis suggests that DM is a risk factor for HCC in 
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in the presence of DM; however, we report significant between-
study heterogeneity. This association did not materially change 
after restriction to studies adjusting for relevant confounders, 
but did suggest a favourable impact of DM treatment with met-
formin. Pooled effect estimates remained significant in sensitivity 
analyses. Few studies investigated other comorbidities, and some 
F I G U R E  2  Forest plot of hazard ratios from longitudinal cohort studies investigating the association of diabetes mellitus with risk of 
progression of chronic hepatitis B infection to hepatocellular carcinoma (HCC). All studies included in meta-analysis were cohort or nested 
case-control studies reporting hazards ratios minimally adjusted for age and sex. The study by Yu et al 96 provided an odds ratio and was 
excluded from the meta-analysis. Dashed vertical lines represent HR based on meta-analysis of all studies by fixed-effect and random-
effects models. The studies for pooling the HR had sufficient quality (quality scores ≥5). CI, confidence interval; DM, diabetes mellitus; HR, 
hazard ratio
TA B L E  2  Effect estimates for cohort studies investigating the association of hypertension with hepatocellular carcinoma risk
Country, Author (Year) Participants, n
HCC Cases, 





Risk ratio (95% 
confidence interval)
Korea, Goh (2020)73 3927 16–19 39.2 (mean, non-DM)
54.9 (mean, DM)
50 aHR 1.19 (0.95 to 1.48)
France, Brichler 
(2019)98
317 27 53 (median) 82 uHR 2.91 (1.33 to 6.35)
Korea, Cho (2019)77 826 86 52 (mean, NAFLD)
54 (mean, non-NAFLD)
61 aHRb  1.38 (0.85 to 2.24)
China, Tan (2019)78 4454 89 45.4 (mean) 68 aHR 0.96 (0.60 to 1.53)
Taiwan, Hsu (2018)54 27,820 802 48.1 (median) 74 uHR 2.13 (1.85 to 2.45)
Hong Kong, Chan 
(2017)82
270 11 43.6 (mean) 75.2 uHR 2.33 (0.68 to 7.98)
US, Chayanupatkul 
(2017)83
8539 317 N/A N/A aHRb  3.15 (1.02 to 9.75)
Korea, Kim (2017)84 1696 24 50 (median) 56.8 aHR 1.70 (0.71 to 4.05)
China, Gao (2013)32c  370 122 54.7 (mean) 86.9 aORb  Not reported (p > 0.1)
Taiwan, Hsu (2014)90 210 35 52.8 (median) 73.3 uHR 1.63 (0.74 to 3.60)
Taiwan, Chen (2008)95 3931 187 45.9 59.3 aHR 0.45 (0.16 to 1.21)
Abbreviations: aHR, adjusted Hazards Ratio; uHR, unadjusted Hazards Ratio.
aAdjusted risk ratios are minimally adjusted for age and sex. 
bAdjusted for age but not sex. 
cCase-control study using hospital controls. 
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TA B L E  3  Effect estimates for associations of other comorbidities and metabolic factors with hepatocellular carcinoma risk
Comorbidity Relative risk measurea  Risk ratio (95% confidence interval)
Dyslipidaemia
Korea, Goh (2020)73 aHR 0.77 (0.63 to 0.95)
Korea, Cho (2019)77 uHR 0.60 (0.26 to 1.39)
China, Tan (2019)78b,c  aHR 0.67 (0.39 to 1.16)
China, Tan (2019)78b,d  aHR 0.49 (0.12 to 2.00)
US, Chayanupatkul (2017)83b  uHR 0.86 (0.38 to 2.00)
Taiwan, Hsu (2014)90 uHR 0.34 (0.05 to 2.50)
Taiwan, Wu (2014)56b,d  aHR 0.87 (0.61 to 1.23)
Obesity (BMI ≥30 kg/m2)
France, Brichler (2019)98 aHR 2.67 (1.04 to 6.84)
US, Chayanupatkul (2017)83 aHRe  2.21 (0.75 to 6.56)
Obesity (BMI >30 kg/m2)
China, Tan (2019)78 aHR 1.59 (0.73 to 3.44)
Obesity (BMI ≥27.5 kg/m2)
Netherlands, Brouwer (2015)87 uHR 1.90 (0.60 to 6.20)
Obesity (BMI ≥27 kg/m2)
Taiwan, Chen (2013)92 uHR 0.84 (0.44 to 1.60)
Obesity (BMI ≥25 kg/m2)
Korea, Lee (2016)99 uHR 0.90 (0.17 to 4.62)
Statin use
Korea, Goh (2020)73 aHR 0.36 (0.19 to 0.68)
Hong Kong, Yip (2020)100 aHR 0.81 (0.73 to 0.90)
Hong Kong, Yip (2018)80 aHR 0.52 (0.26 to 1.01)
CVD
Korea, Cho (2019)77—CVD uHR 1.46 (0.64 to 3.34)
US, Chayanupatkul (2017)83—IHD uHR 1.19 (0.39 to 3.65)
France, Mallet (2017)85—CVD aHR 0.57 (0.53 to 0.62)
Taiwan, Wu (2014)56—ACS aHR 0.66 (0.55 to 0.79)
Taiwan, Wu (2014)56—Cerebrovascular disease aHR 0.50 (0.40 to 0.64)
Other
Hong Kong, Yip (2020)100—Thiazolidinedione use) aHR 0.57 (0.28 to 1.14)
Hong Kong, Yip (2020)100—Metformin use aHR 0.93 (0.85 to 1.02)
Hong Kong, Yip (2020)100—Sulphonylurea use aHR 1.19 (1.09 to 1.30)
Hong Kong, Yip (2020)100—Insulin use aHR 1.32 (1.19 to 1.46)
Hong Kong, Yip (2020)100—Aspirin/clopidogrel use aHR 0.76 (0.68 to 0.85)
Korea, Cho (2019)77—NAFLD aHR 1.67 (1.05 to 2.63)
France, Mallet (2017)85—Renal disease (off dialysis, 
no transplant
aHR 0.34 (0.28 to 0.41)
France, Mallet (2017)85—Renal disease (on dialysis, no 
transplant)
aHR 0.36 (0.22 to 0.60)
France, Mallet (2017)85—Respiratory disease aHR 0.37 (0.33 to 0.42)
Taiwan, Yu (2017)101—Metabolic risk factorsf  aHR HRs for obese or diabetic, obese and diabetic, 
and ≥3 metabolic risk factors were 1.29 (95% 
CI 0.92 to 1.81), 1.18 (0.16 to 8.54) and 2.61 
(1.34 to 5.08), respectively, compared with 
the nonobese and nondiabetic reference 
group.
(Continues)
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comorbidity search terms included in our systematic literature 
search returned few or no results. This highlights the need for fu-
ture investigation of these comorbidities, as antiviral treatment 
cannot eliminate the risk of HCC entirely and therefore significant 
risk factors must be identified in order to inform interventions. 
Although EASL10 and APASL24 guidelines recognize this associa-
tion, it does not inform surveillance, and is not currently consist-
ently described in other recommendations (eg AASLD guidelines23 
do not list DM as a risk factor for HCC).
Some studies investigating comorbidities and their metabolic 
risk factors, specifically dyslipidaemia, reported significantly 
reduced hazards of HCC in participants with these conditions 
compared to those without. This finding was unexpected, and 
observed associations may be confounded by statin use, as only 
two of the seven studies reporting significantly reduced hazards 
of HCC associated with dyslipidaemia adjusted for statin use. 
Alternatively, CHB treatment in secondary care may be con-
founding the analysis, with CHB-infected individuals receiving 
treatment and HCC screening being potentially more likely to 
have comorbid dyslipidaemia diagnosed. However, further inves-
tigation of this association is warranted to minimize the influence 
of confounding factors.
Findings from case-control and cohort studies were not con-
sistent; while the majority of cohort studies reported increased 
hazards of HCC associated with DM, case-control findings were in-
consistent, and indeed three studies reported a significant reduction 
of HCC risk in association with DM. Explanations for such findings 
include confounding, selection bias associated with the study of hos-
pital control groups that enrich for DM,31,32 and chance, especially 
in small studies.31-34
Our findings are consistent with a previous meta-analysis35; we 
provide a comprehensive review of all cohort studies and include 
a larger number of studies. We restricted our analysis to studies 
reporting HRs minimally adjusted for age and sex. However, ad-
justment for covariates and inclusion criteria varied considerably 
between studies, and this may explain some of the between-study 
heterogeneity. Substantial heterogeneity remained in sensitivity 
analyses restricted to studies adjusting for additional key confound-
ers, as adjustment for confounders was variable within these studies 
and populations may not have been comparable. Although baseline 
age and sex characteristics were comparable across studies, there 
was variability regarding exclusion of those with additional comor-
bidities and those on antiviral treatment.
We noted variable definitions of DM, with some studies re-
stricting investigation to type 2 DM, whereas others included 
participants with unspecified DM. Risk factors for types 1 and 2 
diabetes mellitus vary, and heterogeneity in DM definitions could 
therefore contribute to variable study populations and outcomes. 
Global prevalence and incidence estimates for specific DM types 
do not exist, as distinguishing between types often requires ex-
pensive laboratory resources that are not available in many set-
tings. However, most cases of type 1 DM are found in Europe and 
North America, and the large majority of studies included in this 
systematic review and meta-analysis were conducted in Asian 
countries.36
Although HRs did not significantly vary with length of follow-up 
in sensitivity analysis, it is possible that variable lengths of follow-up 
also contributed to between-study heterogeneity. Generally, cancer 
is a chronic disease with a slow development, and preclinical dis-
ease can be present for many years before clinical manifestation; 
follow-up periods <10 years may be insufficient to detect HCC out-
comes. We were unable to provide effect estimates across most 
potential patient subgroups because the subgroups contained small 
numbers of studies, putting subgroup analyses at greater risk of 
chance findings as well as being subject to the influence of multiple 
testing.
The association of DM with HCC we report in this meta-analy-
sis is weaker than those observed in patients with chronic HCV in-
fection. In studies of individuals with chronic HCV infection, risk of 
HCC was elevated ~twofold in the presence of DM.37,38 Previous 
studies also report increased risks of DM in HCV-infected individu-
als as compared to noninfected individuals.39-42 However, this may 
be due to the various extra-hepatic manifestations of HCV which are 
not so clearly associated in HBV infection.43,44
In sensitivity analysis restricted to studies adjusting for cirrhosis, 
the observed association of DM with HCC was attenuated towards 
the null. This may be explained by a confounding of the association 
by cirrhosis, accounted for by an independent association of cirrhosis 
Comorbidity Relative risk measurea  Risk ratio (95% confidence interval)
Taiwan, Wu (2014)56—COPD aHR 0.71 (0.59 to 0.87)
Taiwan, Wu (2014)56—Renal failure aHR 0.84 (0.68 to 1.04)
Taiwan, Chen (2013)92—Metabolic syndrome uHR 1.19 (0.63 to 2.26)
Abbreviations: ACS, acute coronary syndrome; aHR, adjusted Hazards Ratio; BMI, body mass index; COPD, chronic obstructive pulmonary disease; 
CVD, cardiovascular disease; IHD, ischaemic heart disease; NAFLD, nonalcoholic fatty liver disease; uHR, unadjusted Hazards Ratio.
aAdjusted risk ratios are minimally adjusted for age and sex. 
bDefined specifically as hyperlipidaemia. 
cDefined specifically as hypertriglyceridaemia. 
dDefined specifically as hypercholesteraemia. 
eAdjusted for age but not sex. 
fMetabolic risk factors (obesity, diabetes, hypertriglyceridaemia and HT), with exposure groups split into groups of 0, 1, 2 and ≥3 risk factors. 
TABLE 3 (Continued)
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with both DM and HCC, and the absence of cirrhosis from the causal 
pathway that associates DM with HCC. However, if cirrhosis is lo-
cated along this causal pathway, then it can be characterized as a 
mediator rather than a confounder. If cirrhosis is a mediator, then 
adjusting for it would be incorrect.
Past studies support a positive association of DM with HCC 
risk in non-CHB patients,6,7,45 and aetiological investigation has 
suggested that DM can lead to cirrhosis and thereby HCC via fatty 
liver disease,46 as a result of accumulation of fatty acids causing 
oxidative stress driving inflammation and tissue necrosis,47,48 and 
longer-term fibrosis and cirrhosis, thereby increasing HCC risk. 
However, alternative pathways causally associating DM with HCC 
have been suggested, including increased hepatocyte proliferation 
induced by hyperinsulinaemia 49,50 and production of pro-inflam-
matory cytokines that increase cell survival via apoptosis inhibi-
tion.51-53 It is possible that multiple disease pathways associating 
DM with HCC operate simultaneously. Elucidation of the aetiolog-
ical mechanisms underpinning this association will inform future 
epidemiological studies and disease management. Characterizing 
the impact of glycaemic control on HCC risk is also an important 
question for future research.
Three studies adjusted for metformin use,54-56 and in sensitivity 
analysis restricted to these studies, the association between DM and 
HCC remained significant but was attenuated towards the null. It is 
not known the extent to which this is a result of glucoregulation by 
metformin, accomplished by inhibition of hepatic gluconeogenesis 
and improvement of insulin sensitivity in tissues leading to reduced 
oxidative stress in the liver,57 and/or a direct impact of metformin 
in reducing cancer risk via regulation of cellular signalling. Evidence 
from observational studies58-60 and randomized controlled trials 
(RCTs)61 supports a protective effect of metformin against the de-
velopment and progression of cancer in diabetic individuals. There is 
also some RCT evidence for protective effects of metformin against 
progression of certain cancer types in nondiabetic individuals62 al-
though this is not consistent. Multiple large-scale phase III RCTs are 
currently underway63-66 and will provide further information regard-
ing the roles of DM and metformin in cancer development.
We included all studies investigating the association of comorbidities 
with risk of CHB progression to HCC that minimally adjusted for age and 
sex in order to provide a comprehensive review of available evidence. 
However, few studies investigated non-DM comorbidities, preventing 
meta-analysis for these comorbidities. Additionally, we were unable to 
restrict our meta-analysis of DM and HCC to studies adjusting for fur-
ther confounders in addition to age and sex, as few studies minimally 
adjusted for all relevant factors. Publication bias may influence the out-
come, as we restricted our search to the peer-reviewed English-language 
literature, and studies that do not report an association of DM with HCC 
may be less likely to be published. Our results may not be generalizable 
to the global CHB population, as there were a limited number of studies 
from non-Asian countries. The lack of studies from any African countries 
is of concern, given that the region carries both the highest HBV preva-
lence67 and largest mortality burdens for cirrhosis and HCC.68,69
Our finding that DM is a risk factor for HCC in CHB-infected 
individuals suggests that enhanced cancer surveillance may be jus-
tified in patients with CHB and DM to enable early detection and 
treatment. Improvements in guidelines could help to inform more 
consistent approaches to risk reduction. After adjustment for met-
formin use, this association remained significant but was attenuated, 
suggesting a potential benefit of metformin that warrants further 
study. Ongoing investigation is required in order to identify and 
characterize risk factors for HCC, to extend these analyses to di-
verse global populations and to elucidate disease mechanisms in 
order to inform prevention, screening and therapeutic intervention.
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